Reviva Pharmaceuticals Holdings, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $961.68 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2022-03-15
- Reviva Pharmaceuticals Holdings, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $961.68K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2020-12-31 | $961.68K 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |